STOCK TITAN

Celcuity to Participate in the William Blair Biotech Focus Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on cancer treatment, will participate in the William Blair Biotech Focus Conference on July 14-15, 2021. CEO Brian Sullivan is scheduled for a fireside chat at 2 p.m. ET on July 15. A live webcast of the chat can be accessed at this link or through the Investors section of Celcuity's website, with a replay available shortly after the live event.

Celcuity utilizes its CELsignia companion diagnostic platform to analyze live cancer cells and identify patients who may benefit from targeted therapies.

Positive
  • None.
Negative
  • None.

MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the William Blair Biotech Focus Conference to be held July 14-15, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-Founder of Celcuity, is scheduled to present in a fireside chat at 2 p.m. ET on Thursday, July 15, 2021.

A live webcast of the fireside chat will be available at https://wsw.com/webcast/blair59/celc/1901416. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://celcuity.com/investors/events-webcasts/ with a replay available shortly after the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic and therapeutic strategy. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Its therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123

Westwicke ICR
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.



View source version on accesswire.com:
https://www.accesswire.com/654733/Celcuity-to-Participate-in-the-William-Blair-Biotech-Focus-Conference

FAQ

When is Celcuity's presentation at the William Blair Biotech Focus Conference?

Celcuity will present on July 15, 2021, at 2 p.m. ET.

How can I watch Celcuity's fireside chat at the conference?

You can watch the fireside chat live at this link or from the Investors section of Celcuity's website.

What is the purpose of Celcuity's CELsignia platform?

The CELsignia platform analyzes live patient tumor cells to identify cancer patients likely to benefit from targeted therapies.

What is Celcuity's focus as a biotechnology company?

Celcuity focuses on integrated companion diagnostics and developing targeted therapies for cancer treatment.

Celcuity Inc.

NASDAQ:CELC

CELC Rankings

CELC Latest News

CELC Stock Data

442.58M
29.92M
13.05%
81.47%
9.42%
Biotechnology
Services-medical Laboratories
Link
United States of America
MINNEAPOLIS